Leidos has received a prime contract to provide medical product and research development to the US Army Medical Research and Materiel Command (USAMRMC).
Featuring a five-year base performance period and five one-year options, the multiple-award indefinite-delivery, indefinite-quantity (IDIQ) contract has a maximum potential value of $900m, for all awardees, if all options are exercised.
Under the contract, Leidos Life Sciences will provide medical product research and development services to support the missions of the Army Medical Materiel Development Activity, Army Medical Materiel Agency, other subordinate commands of the USAMRMC, Joint Project Manager Medical Countermeasure Systems, and other Department of Defense (DoD) entities responsible for medical product research and development.
Leidos Federal Health deputy group president Jerry Hogge said: "Our distinguished scientists and researchers look forward to providing research and development for medical products to deliver solutions that can help save and improve the lives of our military service members."
Work under this contract is expected to support the entire scope of developing new drugs, vaccines, blood products, and medical devices, as well as medical support equipment, which improves readiness and ensures the provision of high-quality medical and preventive care to the DoD, while maximising survival of medical casualties on the battlefield.
Work is scheduled to be carried out primarily in Frederick, Maryland, US. The company, which has been supporting the USAMRMC for more than 33 years, is one of four contractors eligible to compete for task orders under the IDIQ contract.
Headquartered at Fort Detrick, Maryland, the USAMRMC develops, acquires, provides, and maintains world-class solutions and capabilities to enable medical readiness worldwide.